SCHEMBL2165918

SCHEMBL2165918

O=c1ccc2cc(F)cc(F)c2[nH]1

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CA12 O43570 5/20 0.60
CA9 Q16790 5/20 0.60
DAO P14920 4/20 0.42
DDO Q99489 2/20 0.41
CA1 P00915 1/20 0.38
CA3 P07451 1/20 0.38
CA4 P22748 1/20 0.38
CA6 P23280 1/20 0.38
CA5A P35218 1/20 0.38
CA7 P43166 1/20 0.38
CA13 Q8N1Q1 1/20 0.38
CA14 Q9ULX7 1/20 0.38
CA5B Q9Y2D0 1/20 0.38
F11 P03951 1/20 0.37
AKR1B1 P15121 2/20 0.37
MMP1 P03956 1/20 0.36
MMP2 P08253 1/20 0.36
MMP9 P14780 1/20 0.36
MMP12 P39900 1/20 0.36
HRH4 Q9H3N8 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2171366 0.82 CA12 (0.55) CA12CA9DAODDOCA1
SCHEMBL12559602 0.82 CA12 (0.55) CA12CA9DAODDOCA1
SCHEMBL20563183 0.82 CA12 (0.48) CA12CA9DAODDOCA1
SCHEMBL12472033 0.80 CA9 (0.47) CA12CA9DAODDOCA1
SCHEMBL20660801 0.80 CA12 (0.56) CA12CA9DAODDOCA1
SCHEMBL31058635 0.80 CA12 (0.56) CA12CA9DAODDOCA1
SCHEMBL27364123 0.78 CA12 (0.50) CA12CA9PDE3BPDE3A
SCHEMBL14828635 0.78 CA12 (0.54) CA12CA9DAODDOCA1
SCHEMBL15828546 0.78 CA12 (0.50) CA12CA9DAODDOCA1
SCHEMBL9267952 0.78 CA12 (0.53) CA12CA9DAODDOCA1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110184013-A1 Imidazo[1,2-a]Pyridine Compounds As Receptor Tyrosine Kinase Inhibitors ARRAY BIOPHARMA, INC. 2011-07-28 US disclosed
US-20110184013-A1 Imidazo[1,2-a]Pyridine Compounds As Receptor Tyrosine Kinase Inhibitors ARRAY BIOPHARMA, INC. 2011-07-28 US disclosed
WO-2010039825-A2 IMIDAZO[1,2-a]PYRIDINE COMPOUNDS AS RECEPTOR TYROSINE KINASE INHIBITORS ARRAY BIOPHARMA INC. (US) 2010-04-08 WO disclosed
WO-2010039825-A2 IMIDAZO[1,2-a]PYRIDINE COMPOUNDS AS RECEPTOR TYROSINE KINASE INHIBITORS ARRAY BIOPHARMA INC. (US) 2010-04-08 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110184013-A1 Imidazo[1,2-a]Pyridine Compounds As Receptor Tyrosine Kinase Inhibitors PIM1, PIM2, PIM3 CA12 4834/4885CA9 4288/4885DAO 2429/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.